Naupang kum 2-6 inkarah Covovax enchhin

India rama naupang kum hnih aṭanga kum ruk inkar mi 230-ah Covid vaccine, Covovax enchhinna neih niin, ramchhunga vaccine la naupang ber an nih thu a siamchhuaktu Serum Institute of India chuan Thawhlehni khan a sawi.

Naupangte hi vaccine dose khatna an lak aṭanga ni 21 hnuah dose hnihna hi pek leh an ni ang. Naupang tana vaccine enchhinna hi ram chhunga hospital 10-ah neih niin, May thla tawp lamah an zo thei ang.

Hmun 10-a Covovax paedatric trial neih enpuitu, senior official chuan India rama Covid vaccine enchhinna an neiha age group naupang ber an nih thu a sawi. Covovax paediatric trial phase 2 leh phase 3 hi nikum August thla khan ṭan a ni tawh a, hetah hian naupang 920 an tel a, mi 460 te chu kum 12-17 inkar an ni a, 230 chu kum 7-11 inkar leh 230 dangte chu kum 2-6 inkar an ni. SII bakah hian, Bharat Biotech chuan naupang kum 2-6 inkar tan Covaxin enchhinna hi neih an tum thu an sawi bawk.

SII hian tleirawl tan Covovax enchhin phalna hi an dil hmasa a ni. Tleirawl tan lak a him tawk tih an finfiah hnuah, SII chuan kum 7-11 inkar tana enchhin phalna an dil hnuah kum zat tihniam zelin, kum 2-6 inkar tan an dil leh a ni. Trial design tarlan danin, SII hian kum naupang lam aṭanga ṭanin, mi 100 hnenah vaccine hi a him tawk em tih an enchhin hmasa phawt tih an sawi. "Tleirawl lamah kan ṭan tawh a, chumi hnuah kum 7-11 inkar telh leh an ni. Hemi hnu hian phalna kan hmuh hnuhah kum 2-6 ah kan ṭan leh a ni," tiin official chuan a sawi. Naupangte hi vaccine dose hnih kan pek zawhah thla ruk chhung kan vil zui leh ang, an ti.

American biotechnology firm Novavax siam recombinant nanoparticle protein-based vaccine — NVX-CoV2373 — hi India ramah Covovax tiha sawi a ni. SII leh Novavax thawkdun chuan naupang tan Covovax hi June thla velah an semchhuah hman an beisei.